An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 open-label, one-arm, clinical study to evaluate the efficacy and safety of
DCCR (diazoxide choline) extended-release tablets over 1 year of treatment, in patients with
genetic obesities.